How to transfer my Ozempic prescription to Texas

The demand for GLP-1 weight loss medications like Wegovy, Ozempic, and Mounjaro has surged dramatically over the past few years. As more Americans seek effective solutions for obesity management, one question keeps coming up: Can I get these medications through telehealth, or do I need to see a doctor in person?

The short answer is yes—in most cases, you can legally obtain prescription weight loss medication through telehealth. However, the specific requirements vary by state, and understanding these nuances can help you navigate your options safely and effectively.

This comprehensive guide breaks down everything you need to know about telehealth prescribing for weight loss medications in 2025, including federal regulations, state-specific rules, provider qualifications, and what to expect from a legitimate telehealth service.

Understanding Federal Telehealth Rules for Weight Loss Medications

At the federal level, the rules around telehealth prescribing depend largely on whether a medication is classified as a ‘controlled substance’ under the Drug Enforcement Administration (DEA).

Here’s the crucial distinction: GLP-1 weight loss medications—including Wegovy (semaglutide), Ozempic (semaglutide), and Mounjaro/Zepbound (tirzepatide)—are not controlled substances. This means they’re not subject to the Ryan Haight Act, which requires an in-person medical evaluation before prescribing controlled medications via telemedicine.

What This Means for You

Because these medications aren’t controlled substances, there’s no federal law requiring an in-person visit before a provider can prescribe them via telehealth. A licensed healthcare provider can evaluate you through a video consultation, review your medical history, and send a prescription electronically to your pharmacy—all without you stepping foot in a physical clinic.

That said, federal telehealth flexibilities for controlled substances (like ADHD medications or certain pain medications) remain in a temporary status. The DEA extended pandemic-era telehealth rules through December 31, 2025, allowing providers to prescribe controlled substances via telehealth without an initial in-person exam. While this doesn’t directly affect GLP-1 medications, it reflects the broader trend toward making telehealth more accessible.

The Current Regulatory Landscape

The telehealth landscape continues to evolve. In November 2024, the DEA and HHS announced a third extension of telemedicine flexibilities through the end of 2025, giving regulators more time to develop permanent rules. Congress is also considering legislation like the TREATS Act, which would make some telehealth prescribing flexibilities permanent, particularly for substance use disorder and mental health treatment.

For weight loss medications specifically, the regulatory environment is stable and supportive. No federal restrictions prevent telehealth prescribing of GLP-1 medications, and the trend is moving toward greater access with appropriate clinical safeguards.

Free consultations available with select providers only.

Get a free consultation

And find an affordable, caring specialist.

Find a provider

Free consultations available with select providers only.

State-Specific Telehealth Requirements: What You Need to Know

While federal law provides a general framework, each state has its own rules governing telehealth practice and prescribing. Some states have additional requirements that providers must follow, even though federal law doesn’t mandate them.

States Requiring an Initial In-Person Exam

Several states require or strongly recommend an initial in-person physical examination before prescribing weight loss medications via telehealth:

Arkansas has some of the strictest telehealth rules in the country. Providers must conduct the first examination in person to establish a valid patient-provider relationship before prescribing weight loss medications through telemedicine.

Delaware requires an initial physical exam in person, though follow-up visits can be conducted via telehealth once that relationship is established.

Georgia mandates an in-person exam prior to telehealth prescribing of weight loss medications. However, Georgia recently expanded prescriptive authority for nurse practitioners and physician assistants, allowing them to prescribe Schedule II controlled substances with physician delegation—a significant step forward for access.

Mississippi requires patients to be seen in person initially for weight management therapy evaluation. The state is currently considering legislation to grant nurse practitioners independent practice authority, which could further expand telehealth access.

New Jersey has particularly comprehensive requirements: providers must conduct an extensive initial evaluation including a physical exam, laboratory work, psychological screening, and documentation of a personalized diet and exercise plan before prescribing any weight-loss medication.

North Dakota expects a hands-on initial evaluation for weight-loss treatment, per state medical board guidance, though the state fully embraces telehealth for ongoing care.

South Carolina requires an initial in-person visit and periodic evaluations. Providers must follow established protocols when prescribing weight loss medications.

Texas generally expects an initial in-person exam prior to telehealth prescribing of weight loss medications, reflecting the state’s cautious approach to telemedicine. Texas also maintains strict oversight of nurse practitioner and physician assistant prescribing, requiring physician delegation agreements.

Utah encourages an initial in-person baseline evaluation, though the state has recently expanded nurse practitioner autonomy and widely supports telehealth.

Virginia requires a comprehensive initial work-up including a physical examination, laboratory tests, and a documented diet and exercise plan. The state also mandates a follow-up visit within 30 days of starting therapy and requires providers to document informed consent covering all risks associated with weight-loss medication therapy.

States With No In-Person Requirement

Many states allow providers to establish a patient relationship and prescribe weight loss medications entirely through telehealth, with no in-person visit required:

California explicitly permits telehealth evaluations as sufficient for prescribing. Nurse practitioners in California can practice independently after gaining three or more years of experience, making telehealth weight loss services widely accessible.

Connecticut has permanent telehealth laws with no in-person mandate. The state does require that obesity treatment include behavioral counseling and diet/exercise planning alongside medication.

Florida allows telehealth prescribing without requiring an in-person physical exam. However, Florida imposes specific conditions: patients must have a BMI of 30 or higher and must be seen for follow-up visits at least every three months during treatment.

Illinois has no special restrictions on telehealth for weight loss medications beyond standard medical practice. The state mandates electronic prescribing for all medications, streamlining the process.

New York explicitly allows telehealth evaluations to suffice for prescribing weight loss medications. Nurse practitioners gained full practice authority in 2022, and the state has required e-prescribing since 2016.

Pennsylvania has no in-person mandate for GLP-1 medications, though nurse practitioners still operate under physician collaboration agreements as the state’s independent practice law awaits full implementation.

Washington is a pioneering telehealth state with no in-person requirements. The state has full nurse practitioner independence and robust privacy protections under the My Health My Data Act—particularly important given the sensitive nature of weight-loss health information.

Special State Requirements to Know

Beyond in-person exam rules, some states have additional requirements:

Florida requires follow-up visits at least every three months and documentation that the patient meets BMI criteria (≥30 or ≥27 with comorbidities).

Connecticut mandates that providers include behavioral counseling and lifestyle modification plans as part of obesity treatment.

New Jersey and Virginia both require extensive documentation of risks, benefits, and alternatives, along with formal informed consent specifically for weight-loss medication therapy.

Who Can Prescribe Weight Loss Medications Via Telehealth?

Not all providers have the same prescribing authority. Understanding who can prescribe these medications—and under what circumstances—is important when choosing a telehealth service.

Medical Doctors and Doctors of Osteopathic Medicine

MDs and DOs can prescribe GLP-1 weight loss medications via telehealth in any state where they hold an active medical license. This is the most straightforward pathway, as physicians have full prescriptive authority.

Nurse Practitioners

Nurse Practitioners (NPs) can prescribe weight loss medications in all 50 states, but their level of independence varies significantly:

Independent Practice States: In about half of U.S. states—including California, New York, Washington, Arizona, and 30+ others—nurse practitioners can practice independently without physician oversight after meeting experience requirements (typically 2-3 years). In these states, an NP can evaluate you, prescribe medication, and manage your care entirely on their own.

Collaborative Practice States: In states like Florida, Texas, Pennsylvania, and Illinois, nurse practitioners must have a collaboration agreement or supervisory arrangement with a physician. The NP can still prescribe weight loss medications, but there must be physician oversight of the practice.

Recent Expansions: As of 2025, 34 states plus the District of Columbia have granted nurse practitioners full practice authority. This trend continues to expand, with several states (including Mississippi and Pennsylvania) considering legislation to eliminate collaboration requirements.

Physician Assistants

Physician Assistants (PAs) can also prescribe GLP-1 medications, though they typically work under physician supervision or delegation in most states. The specific scope varies by state medical board rules and the individual PA’s collaborative agreement.

Important note: Georgia recently passed legislation allowing nurse practitioners and physician assistants to prescribe Schedule II controlled substances with physician delegation—though this doesn’t directly affect GLP-1 medications (which aren’t controlled), it signals growing recognition of advanced practice providers’ capabilities.

What to Expect From a Legitimate Telehealth Weight Loss Service

Not all telehealth services are created equal. Understanding what constitutes appropriate care helps you identify reputable providers and avoid potentially dangerous ‘prescription mills.’

Comprehensive Medical Evaluation

A legitimate telehealth provider will conduct a thorough evaluation that includes:

• Detailed medical history: Including any chronic conditions, previous weight loss attempts, surgical history, and family medical history
• Current medications and allergies: To check for potential interactions and contraindications
• Mental health screening: GLP-1 medications have specific contraindications related to depression and eating disorders
• Vital signs and measurements: You’ll need to provide accurate current weight, height, and calculate BMI
• Laboratory work: Many providers require recent lab results (typically within the past year) including metabolic panel, thyroid function, and possibly A1C

This evaluation typically occurs via live video consultation—not just an online questionnaire. Reputable providers won’t guarantee you a prescription before the evaluation.

Eligibility Criteria

GLP-1 medications for weight loss are FDA-approved for specific patient populations:

• Adults with BMI ≥30 (obesity), OR
• Adults with BMI ≥27 with at least one weight-related comorbidity (such as type 2 diabetes, hypertension, or high cholesterol)

You should have attempted lifestyle modifications (diet and exercise) unless medically inadvisable. These aren’t cosmetic weight loss drugs for people who are slightly overweight—they’re medical treatments for obesity as a chronic disease.

Contraindications and Safety Screening

Legitimate providers will screen for contraindications including:

• Personal or family history of medullary thyroid carcinoma (all GLP-1s carry an FDA boxed warning)
• Multiple Endocrine Neoplasia syndrome type 2 (MEN2)
• Pregnancy or plans to become pregnant (must discontinue before conception)
• Active gallbladder disease or history of pancreatitis
• Severe gastrointestinal disorders like gastroparesis
• History of severe allergic reactions to GLP-1 medications

If you have any of these conditions, a reputable provider won’t prescribe these medications.

Treatment Planning and Education

Your provider should discuss:

• Realistic expectations: Gradual weight loss over several months, not rapid results
• Lifestyle modifications: Medication works best alongside diet changes and increased physical activity
• Side effects: Common issues like nausea, vomiting, diarrhea, and constipation
• Administration: How to properly inject the medication (all current GLP-1 weight loss medications are injectable)
• Dosage titration: Starting low and gradually increasing to minimize side effects

Many states explicitly require documentation of a diet and exercise plan alongside medication therapy.

Informed Consent

Several states (including New Jersey, Virginia, and Florida) require formal informed consent documents specifically for weight-loss medication. Even where not legally required, reputable providers will ensure you understand:

• Benefits and limitations of treatment
• Potential side effects and serious risks
• Alternative treatments
• The importance of follow-up care
• When to seek emergency medical attention

Regular Follow-Up and Monitoring

This is critical: Weight loss medications require ongoing monitoring. Legitimate telehealth services will:

• Schedule a follow-up visit within 1 month of starting medication
• Conduct regular check-ins (typically every 2-3 months) to assess progress, side effects, and adjust dosage
• Require periodic lab work to monitor for adverse effects
• Discontinue medication if it’s not safe or effective for you

Some states mandate specific follow-up schedules—for example, Florida requires at least one follow-up every three months, and Virginia requires a check-in within 30 days of starting treatment.

Transparent Pricing and Licensing

A reputable telehealth provider will be upfront about:

• The cost of consultations and follow-up visits
• Whether they accept insurance or operate on a cash-pay basis
• The provider’s credentials and state licensure
• Where the provider is licensed to practice

Provider licensing is crucial: Your telehealth provider must be licensed in the state where you physically reside at the time of the consultation. Many telehealth companies work with providers licensed in multiple states to ensure compliance.

Services like Klarity Health maintain networks of licensed providers across multiple states, accept both insurance and cash payment, offer transparent pricing, and prioritize clinical appropriateness over simply writing prescriptions.

Red Flags: What to Avoid

Unfortunately, the popularity of medications like Wegovy and Ozempic has attracted some less scrupulous operators. Watch out for these warning signs:

Guaranteed Prescriptions

Red flag: Any service that guarantees you’ll get a prescription without a thorough medical evaluation is operating outside appropriate medical standards. Legitimate providers evaluate each patient individually and will decline to prescribe if the medication isn’t appropriate.

Compounded or ‘Alternative’ Versions

In May 2025, the FDA banned most retail compounding of semaglutide for weight loss after declaring the Wegovy shortage resolved. While compound pharmacies served an important role during shortages, purchasing compounded versions of FDA-approved medications now carries significant risks:

• Inconsistent dosing and potency
• Contamination risks
• Lack of FDA oversight
• Potentially counterfeit or overseas sources

Legitimate telehealth providers prescribe FDA-approved medications filled through licensed U.S. pharmacies.

No Follow-Up or Monitoring

Red flag: Services that don’t schedule regular follow-ups or don’t want to monitor your progress aren’t providing appropriate medical care. Weight loss medication requires ongoing oversight.

Unclear Provider Credentials

Red flag: If you can’t identify who your provider is, what their credentials are, or which state they’re licensed in, that’s a major concern. Reputable services are transparent about their providers’ qualifications.

Skipping Informed Consent

Red flag: If a service doesn’t discuss risks, side effects, and alternatives, they’re not meeting the standard of care. You should never feel rushed or pressured into treatment.

Unusually Low Prices

If pricing seems too good to be true—especially if significantly below market rate—it may indicate the use of non-FDA-approved products, inadequate provider oversight, or other shortcuts that compromise your safety.

The Cost of Telehealth Weight Loss Treatment

Understanding the financial aspect of telehealth weight loss treatment helps set realistic expectations.

Consultation Fees

Telehealth consultations for weight loss typically range from $49 to $200 for an initial visit, with follow-up visits costing $40 to $150. Some services charge a monthly membership fee that includes consultations.

Medication Costs

The medication itself is often the biggest expense:

• With insurance: If your plan covers weight loss medications (many don’t), copays might range from $25 to $100+ per month
• Without insurance: List prices for brand-name GLP-1s can be $900-$1,350+ per month
• Manufacturer savings programs: Novo Nordisk and Eli Lilly offer savings cards that can reduce costs significantly for eligible patients—sometimes to as low as $25 per month

Cash-Pay Programs

Some telehealth services offer bundled pricing that includes consultations and medication sourcing assistance. Cash-pay models can sometimes be more affordable than going through insurance, particularly if your insurance doesn’t cover weight loss medications.

Klarity Health accepts both insurance and cash payment, providing flexibility based on your coverage and financial situation. Their transparent pricing means you know what to expect before committing to treatment.

The Klarity Health Approach to Telehealth Weight Loss Care

When you’re ready to explore telehealth options for weight loss medication, choosing the right provider makes all the difference.

Klarity Health offers a clinically sound, patient-centered approach to weight management:

Comprehensive Evaluation

Klarity’s licensed providers conduct thorough video consultations, reviewing your complete medical history, current health status, weight loss goals, and previous attempts at weight management. They’ll ensure you meet clinical criteria and don’t have contraindications before prescribing medication.

Qualified, Licensed Providers

All Klarity providers are licensed MDs, DOs, or nurse practitioners (in states with appropriate NP authority) who are credentialed in your state of residence. You’ll know exactly who your provider is and their qualifications.

Insurance and Cash-Pay Flexibility

Unlike some telehealth services that only accept cash, Klarity works with insurance plans and also offers transparent cash-pay pricing. This flexibility helps make weight loss treatment more accessible.

Ongoing Support and Monitoring

Klarity schedules regular follow-ups to monitor your progress, manage side effects, adjust medication as needed, and provide support for the lifestyle changes that make weight loss sustainable. This isn’t a ‘prescription and forget it’ service—it’s comprehensive care.

Evidence-Based Treatment

Klarity’s approach aligns with current medical guidelines and state regulations. Providers emphasize that medication is one tool among many, and success requires commitment to healthy eating, physical activity, and behavioral change.

Looking Ahead: The Future of Telehealth Weight Loss Treatment

Telehealth for weight loss management is here to stay, and the regulatory environment continues to evolve in favor of greater access with appropriate safeguards.

Expected Federal Developments

The DEA is expected to extend or replace current telehealth flexibilities before they expire at the end of 2025. While this mainly affects controlled substances, it signals federal support for telemedicine broadly.

Congress may pass legislation like the TREATS Act, which would permanently allow telehealth prescribing in certain situations—reflecting recognition of telemedicine’s value for expanding access to care.

State-Level Changes

Multiple states are considering or passing legislation to:

• Expand nurse practitioner independence (bills pending in Mississippi, Pennsylvania, and others)
• Streamline telehealth licensing through interstate compacts
• Clarify and modernize telehealth practice standards

The trend is clearly toward making telehealth more accessible while maintaining clinical standards.

Increased Scrutiny of Safety and Quality

As telehealth weight loss services proliferate, regulators are paying closer attention to ensure patient safety. The FDA’s 2025 ban on compounded semaglutide demonstrates this focus. State medical boards are actively monitoring telehealth practices for compliance with standards of care.

For patients, this means choosing established, reputable services becomes even more important. Providers who cut corners or prioritize volume over quality will face increasing regulatory scrutiny.

Frequently Asked Questions

Do I need to see a doctor in person before getting weight loss medication?

At the federal level, no—GLP-1 medications aren’t controlled substances, so there’s no federal requirement for an in-person visit. However, some states (including Arkansas, Delaware, Georgia, Mississippi, New Jersey, North Dakota, South Carolina, Texas, Utah, and Virginia) require or expect an initial in-person examination. Check your state’s specific rules in our table above.

Can nurse practitioners prescribe weight loss medications via telehealth?

Yes, in all states. However, in some states they must work under physician supervision or collaboration, while in others (currently 34 states plus DC) they can practice independently. The level of oversight depends on your state’s laws.

Is it safe to get weight loss medication through telehealth?

Yes, when done properly. A legitimate telehealth service conducts the same thorough evaluation, screening, and ongoing monitoring as you’d receive in person. The key is choosing a reputable provider who follows clinical guidelines and state regulations.

Will my insurance cover telehealth visits for weight loss medication?

Many insurance plans now cover telehealth visits at the same rate as in-person visits. However, coverage for the weight loss medications themselves varies widely—many plans still don’t cover medications prescribed specifically for weight loss, even FDA-approved ones like Wegovy.

How quickly can I get a prescription through telehealth?

If you’re medically eligible, you may receive a prescription after your first consultation—often within 24-48 hours of your initial appointment. However, some states requiring in-person exams or additional lab work may delay the process.

What’s the difference between Wegovy and Ozempic?

Both contain semaglutide, but Wegovy is FDA-approved specifically for weight management at a higher dose (2.4mg), while Ozempic is approved for type 2 diabetes at lower doses. Doctors often prescribe Ozempic ‘off-label’ for weight loss when Wegovy is unavailable or insurance won’t cover it.

How long will I need to take weight loss medication?

GLP-1 medications are intended for long-term use as part of chronic weight management. Most patients regain weight if they stop the medication, so treatment is typically ongoing unless side effects or other factors require discontinuation.

Taking the Next Step

If you’re struggling with obesity and wondering whether telehealth weight loss treatment might be right for you, the answer depends on your individual health profile, state regulations, and commitment to comprehensive lifestyle change alongside medication.

Ready to explore your options? Consider scheduling a consultation with a reputable telehealth provider like Klarity Health. Their licensed providers can assess your eligibility, discuss whether GLP-1 medications are appropriate for you, and create a personalized treatment plan that fits your needs and goals.

Remember: effective, sustainable weight loss requires more than just medication. It requires partnership with qualified healthcare providers who will support you through every step of your journey—and telehealth has made that partnership more accessible than ever before.

References and Research

Research Currency StatementVerified as of: December 17, 2025

Top 5 Key Citations

1. U.S. Drug Enforcement Administration (DEA) and HHS. ‘DEA and HHS Extend Telemedicine Flexibilities through 2025.’ Official press release, November 15, 2024. Available at: www.dea.gov. Primary source confirming federal telehealth flexibility extension for controlled substances through December 31, 2025.

2. Goodwin Procter LLP. ‘The Changing Regulatory and Reimbursement Landscape for Weight-Loss Drugs.’ Healthcare + Life Sciences Client Alert, March 27, 2024. Available at: www.goodwinlaw.com. Comprehensive legal analysis of state-specific requirements for prescribing weight-loss medications, including detailed rules for Florida, New Jersey, and Virginia.

3. McDermott Will & Emery LLP. ‘DEA Extends Telemedicine Flexibilities for Controlled Substance Prescribing Through December 31, 2025.’ Legal update, November 18, 2024. Available at: www.mwe.com. Expert legal analysis explaining Ryan Haight Act exemptions and current DEA telemedicine policy status.

4. Reuters News. ‘Hims to cut 4% of workforce amid ban on weight-loss drug copies.’ Healthcare news report, May 30, 2025. Available at: www.reuters.com. Confirms FDA enforcement action banning compounded semaglutide as of May 2025.

5. Nextech Systems. ‘Know Your State’s Laws Around Semaglutide: A Comprehensive Guide.’ Healthcare compliance blog, April 11, 2025. Available at: www.nextech.com. State-by-state compilation of prescribing requirements and restrictions for GLP-1 medications, updated for 2025.

Additional sources: 15 of 18 total references used for this article were published in 2024-2025, ensuring currency and accuracy. State medical board regulations were verified through official state government websites and cross-referenced with legal analyses. All clinical information aligns with current FDA guidance and established standards of care for obesity management.

Source:

• https://www.axios.com/2024/11/18/covid-telehealth-prescribing-extended-adderall#:~:text=The%20Drug%20Enforcement%20Administration%20,year%20extension
• https://www.dea.gov/documents/2024/2024-11/2024-11-15/dea-and-hhs-extend-telemedicine-flexibilities-through-2025#:~:text=telemedicine%20flexibilities%20through%20December%2031%2C,HHS%20on%20November%2015%2C%202024
• https://www.mwe.com/insights/dea-signals-extension-of-telemedicine-flexibilities-for-controlled-substance-prescribing-for-2026/#:~:text=A%20new%20rule%20posted%20on,date%20of%20December%2031%2C%202025
• https://www.mwe.com/insights/dea-extends-telemedicine-flexibilities-for-controlled-substance-prescribing-through-december-31-2025/#:~:text=,a%20final%20set%20of%20regulations
• https://www.mwe.com/insights/dea-extends-telemedicine-flexibilities-for-controlled-substance-prescribing-through-december-31-2025/#:~:text=31%2C%202024.%20,In%20February%202023%2C%20the%20DEA
• https://www.mwe.com/insights/dea-extends-telemedicine-flexibilities-for-controlled-substance-prescribing-through-december-31-2025/#:~:text=to%20perform%20an%20in,rule%20regarding%20telemedicine%20prescribing%20of
• https://www.whitehouse.senate.gov/news/release/whitehouse-murkowski-warner-blackburn-urge-white-house-and-dea-to-extend-telehealth-flexibilities-for-substance-use-disorder-and-mental-health-treatment/#:~:text=Whitehouse%2C%20Murkowski%2C%20Warner%2C%20Blackburn%20Urge,substance%20use%20disorder%20treatment%20Washington
• https://natlawreview.com/article/arkansas-it-again-telemedicine-regulation-arkansas-undergoes-additional-change#:~:text=Arkansas%20currently%20has%20one%20of,person%20examination
• https://www.nextech.com/blog/semaglutide-laws-by-state#:~:text=Who%20can%20prescribe%20semaglutide%3F%20,
• https://natlawreview.com/article/arkansas-it-again-telemedicine-regulation-arkansas-undergoes-additional-change#:~:text=Arkansas%20currently%20has%20one%20of,encounter%20to%20establish%20a%20valid